Pethidine
Viewing r1 — May 10, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Pethidine (meperidine) — also known as Demerol — is a synthetic opioid of the 4-phenylpiperidine class. It is the prototype of the phenylpiperidine family, the structural ancestor of fentanyl. Pethidine is a full agonist at μ-opioid receptors, producing its effects by suppressing pain signalling while simultaneously blocking serotonin reuptake and sodium channels.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
morphine, fentanyl, oxycodone +4 moremorphine, fentanyl, oxycodone, hydromorphone, heroin, codeine, tramadol show less
Synthesized by Otto Eisleb at IG Farben in 1938 during a search for antispasmodic agents, pethidine was the first wholly synthetic opioid analgesic.[1] By 1975, approximately 60% of US physicians named it their preferred opioid for acute pain.[2] Accumulating evidence of neurotoxicity from its metabolite normeperidine led to its removal from the WHO List of Essential Medicines by 2003, and clinical use has contracted sharply.[3]
Subjective effects include analgesia, euphoria, sedation, and anxiolysis. The experience is a warm, diffuse opioid calm distinguished from morphine by a mild activating quality at lower doses, dilated pupils rather than constricted ones, and a faster heartbeat reflecting pethidine's anticholinergic component. Nausea, dizziness, and dry mouth are common unsought effects.
Pethidine produces rapid physical dependence and carries high acute and chronic toxicity. Its defining danger is the metabolite normeperidine, which accumulates with repeated dosing and causes seizures that naloxone cannot reverse[4] — a risk that escalates with kidney impairment, advanced age, and use exceeding 48 hours.[3] Eight decades of clinical use provide extensive safety data, though quantitative receptor binding affinities remain uncharacterised.
History[edit]
Discovery
Pethidine was synthesized in 1938 by Otto Eisleb at IG Farben in Germany during a programme aimed at developing new antispasmodic agents — not analgesics.[1] Its opioid-like pain-relieving properties were identified by Otto Schaumann, who published the finding in 1939 under the trade name "Dolantin".[1] The accidental discovery — an antispasmodic screen yielding the first fully synthetic opioid — established the 4-phenylpiperidine scaffold that would later produce fentanyl and every subsequent phenylpiperidine opioid.[5]
Clinical dominance
Introduced to the US market as Demerol in 1943,[2] pethidine's oral availability, shorter duration than morphine, and perceived lower abuse liability drove rapid adoption. By 1975, approximately 60% of US physicians reported it as their preferred opioid for acute pain.[2] It became the standard analgesic in obstetrics, postoperative care, and emergency departments throughout the English-speaking world.
Decline and modern status
Systematic recognition of normeperidine neurotoxicity in the 1980s — documented through case reports of seizures in cancer patients,[4] kidney failure,[6] and sickle cell disease[7] — triggered progressive institutional restrictions. Pethidine was removed from the WHO List of Essential Medicines by 2003,[3] and the 2023 AGS Beers Criteria classified it as a medication to always avoid in older adults.[8] It retains limited clinical use for post-anaesthetic shivering[9] and, in some jurisdictions, labour analgesia — though Cochrane evidence suggests inferior efficacy compared to alternatives.[10]
The name "pethidine" derives from the German trade-name construction common at IG Farben; "meperidine" is the USAN adopted in American pharmacology. Demerol — the brand name under which the drug was marketed in the United States — became virtually synonymous with injectable pain suppression in American hospitals and entered popular culture as shorthand for powerful opioid analgesia.
Chemistry[edit]
Structural class
Pethidine is the prototype of the 4-phenylpiperidine opioid class — a structural family defined by a phenyl ring at the 4-position of a piperidine ring.[5] Its relative simplicity compared to morphine's pentacyclic skeleton demonstrated that complex ring structures were unnecessary for opioid receptor activation, a finding that reshaped analgesic drug design. Systematic modification of the pethidine scaffold produced the entire fentanyl family and numerous other clinical opioids.
The molecule consists of a piperidine ring bearing an N-methyl group, a 4-phenyl substituent, and a 4-ethoxycarbonyl (ester) group. The ester moiety is essential for analgesic activity and is also the site of the compound's primary metabolic degradation.
Molecular properties
| Molecular formula | C₁₅H₂₁NO₂ |
| Molecular weight | 247.33 g/mol |
Stereochemistry
Pethidine is achiral — it possesses no chirality centre and is used clinically as a single constitutional isomer without stereochemical considerations.
Physical properties
The free base is a colourless liquid at room temperature. The hydrochloride salt — the form used in all pharmaceutical preparations — is a white crystalline powder freely soluble in water, with a melting point of 187–188°C.[11]
Pharmacology[edit]
Mechanism of action
Pethidine is a full agonist at the μ-opioid receptor, which mediates its primary analgesic, sedative, euphoric, and respiratory depressant effects.[5][3] Unlike morphine and most clinical opioids, pethidine engages several additional targets that produce a distinctive profile.
It also activates κ-opioid receptors, which mediate its clinically unique anti-shivering effect.[3][9] Pethidine blocks serotonin reuptake — a property shared with tramadol but absent from morphine and fentanyl — creating serotonin syndrome risk when combined with MAOIs or SSRIs.[12][13]
Additional pharmacological activity includes blockade of dopamine and norepinephrine transporters, contributing a mild stimulant quality;[3] voltage-gated sodium channel blockade providing local anaesthetic properties;[13] anticholinergic activity producing tachycardia and pupil dilation rather than the bradycardia and pupil constriction typical of other opioids;[5][13] and histamine release causing vasodilation and itching.[13]
Pharmacokinetics
Oral bioavailability is approximately 50% in healthy adults, rising to 80–90% in liver impairment due to reduced first-pass metabolism.[2][14] Peak plasma concentration after oral dosing occurs at 60–120 minutes. The parent compound half-life is 3–5 hours in healthy adults,[3][2] extending to 7–11 hours in liver disease.[2]
Pethidine is metabolised in the liver to two primary products: normeperidine (norpethidine), an active metabolite with half the analgesic potency but twice the seizure-inducing potency of the parent compound;[3] and meperidinic acid, which is inactive. Normeperidine's half-life of 8–21 hours[3][2] far exceeds the parent compound's, meaning it accumulates with repeated dosing — particularly in kidney impairment. Excretion is renal.[2]
Neuroscience[edit]
Where it acts
μ-Opioid receptor activation in the ventral tegmental area disinhibits dopamine neurons projecting to the nucleus accumbens, producing the euphoria and reinforcement that drive pethidine's high abuse liability.[15] Concurrently, μ-receptor activation in the periaqueductal grey and spinal cord dorsal horn drives descending pain inhibition, producing analgesia supplemented by sodium channel blockade at the spinal level.[13]
Pethidine's additional dopamine and NET blockade[3] may amplify reward signalling beyond what pure μ-agonists produce. Its clinically unique anti-shivering effect arises from κ-opioid receptor activation in hypothalamic thermoregulatory centres, lowering the shivering threshold independently of core temperature changes.[9]
Tolerance and adaptation
Chronic μ-opioid receptor activation drives tolerance through receptor phosphorylation, internalisation, and downstream signalling changes.[15] As analgesic tolerance develops and doses escalate, normeperidine production increases proportionally — elevating seizure risk precisely when the therapeutic benefit diminishes.
Serotonin reuptake blockade elevates synaptic serotonin in raphe-cortical projections,[12] creating the substrate for serotonin syndrome when combined with monoamine oxidase inhibitors or SSRIs.[16]
The specific mechanism by which normeperidine produces seizures remains unknown — the effect is not reversed by naloxone, ruling out opioid receptors, but the actual target has not been established. Whether pethidine's DAT blockade produces measurably greater reinforcement than equianalgesic morphine has never been tested in controlled human studies.
Subjective Effects[edit]
Pethidine produces a classical opioid state — warmth, pain suppression, euphoria, and sedation — overlaid with anticholinergic features that distinguish it from morphine-type compounds. At lower doses a mild activating quality emerges from dopamine and NET blockade, giving way to deeper sedation as dose increases. Set and setting modulate the experience moderately: clinical administration under pain conditions emphasises analgesia, while use in comfortable environments foregrounds the euphoric warmth.
In comparative terms, pethidine sits between morphine (longer-acting, more sedating, more constipating) and tramadol (weaker opioid activity, stronger serotonergic contribution, lower respiratory depression risk). Users historically described pethidine's body euphoria as distinctively "clean" relative to morphine, though this coexists with higher nausea incidence.
Effect Grid
Full analgesic effect with clear cognitive euphoria, pronounced sedation, and enveloping body warmth. Tactile euphoria is prominent — surfaces feel pleasurable against the skin. Anxiety suppression is strong. Thought deceleration and focus suppression are noticeable. The characteristic 'clean' warmth historically distinguished pethidine from morphine's heavier sedation.
Nausea affects a majority of users and may progress to vomiting. Constipation develops. Respiratory depression is clinically present. Tachycardia from anticholinergic activity is measurable. Dry mouth is pronounced. Motor control impairment makes coordination unreliable.
Duration is 3-5 hours. Compulsive redosing urge is significant due to the relatively short effect window combined with strong euphoria. Each redose increases normeperidine accumulation and seizure risk.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Dreaming enhancement · Proprioceptive distortion · Visual haze / noise · Tinnitus · Visual processing suppression
Visual processing suppression
Sedation · Tactile euphoria · Spontaneous body sensations · Constipation · Nausea · Bodily heaviness · Breathing alteration · Dizziness · Muscle relaxation · Physical fatigue · Appetite suppression · Dry mouth · Sexual arousal suppression · Excessive sweating · Tingling / electric sensations · Seizure threshold reduction · Abnormal heartbeat · Heart rate perception changes · Temperature dysregulation · Vomiting · Involuntary body movements · Restlessness · Stimulation · Trembling · Muscle tension · Pain enhancement · Bodily dissociation
Constipation · Nausea · Bodily heaviness · Breathing alteration · Dizziness · Muscle relaxation · Physical fatigue · Appetite suppression · Dry mouth · Sexual arousal suppression · Excessive sweating · Tingling / electric sensations · Abnormal heartbeat · Heart rate perception changes · Temperature dysregulation · Vomiting · Involuntary body movements · Restlessness · Stimulation · Trembling · Muscle tension · Pain enhancement · Bodily dissociation
Focus suppression · Thought deceleration · Analysis suppression · Information processing suppression · Memory suppression · Motivation suppression · Confusion · Thought disorganization · Cognitive dysphoria · Delirium
Information processing suppression · Memory suppression · Motivation suppression · Confusion · Thought disorganization · Cognitive dysphoria
Irritability
Depersonalization
Timeline
Gradual emergence of warmth and mild anxiolysis. First awareness of mood shift and subtle body relaxation. Effects build slowly due to oral absorption and first-pass metabolism.
Maximum analgesia, euphoria, body warmth, and sedation. Tactile euphoria prominent. Anticholinergic effects (tachycardia, mydriasis, dry mouth) fully manifest.
Sustained analgesic effect with steady sedation. Euphoria softens but warmth persists. Nausea may continue or resolve.
Analgesic effect fading. Increasing awareness of baseline state. Restlessness or mild irritability possible as effects wane.
Residual sedation and possible normeperidine-related effects (irritability, tremor in heavy or repeated users). Mild constipation persists. Mood may be slightly flat.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- High
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- morphine · fentanyl · oxycodone
Toxicity
Pethidine carries high acute and chronic toxicity. Its toxicity profile is distinguished from other opioids by two unique liabilities: the neurotoxic metabolite normeperidine and serotonin syndrome risk. Neither is shared by morphine, fentanyl, or hydromorphone.
Acute toxicity
Acute overdose produces respiratory depression, decreased consciousness, and — unlike other opioids — dilated pupils and rapid heartbeat due to anticholinergic activity.[3][5] Additional signs include shallow or absent breathing, blue discolouration of the skin, seizures from normeperidine, and circulatory collapse.[3]
No human lethal dose has been established.safety citation needed Combination with other depressants (alcohol, benzodiazepines, other opioids, barbiturates) produces additive respiratory depression that is frequently fatal.[3]
Normeperidine neurotoxicity
The defining toxicity concern unique to pethidine is accumulation of its metabolite normeperidine. With a half-life of 8–21 hours — far exceeding the parent compound's 3–5 hours — normeperidine builds up with repeated dosing, especially in kidney impairment.
Clinical manifestations include tremors and muscle jerks in patients on high cumulative doses,[4] seizures in kidney failure,[6] and seizures with agitation in sickle cell disease.[7] Risk factors include cumulative doses exceeding 600 mg per 24 hours, use exceeding 48 hours, kidney impairment, and advanced age.
Normeperidine-induced seizures are not reversible by naloxone. Standard opioid overdose reversal is insufficient for pethidine neurotoxicity. Benzodiazepines are the treatment of choice for normeperidine seizures.
Serotonin syndrome
Pethidine is one of the few opioids that can trigger serotonin syndrome, due to its serotonin reuptake blockade. The MAOI–pethidine combination can produce hyperthermia, muscle rigidity, involuntary muscle contractions, and death.[16][18][13] SSRI combinations also carry serotonin syndrome risk, confirmed in both animal models and clinical reports.[12][18]
Psychological Risks
Pethidine produces the standard psychological risks of μ-opioid agonists: euphoria-driven psychological dependence, cognitive impairment during intoxication, and compulsive drug-seeking behaviour. In older adults, pethidine is associated with higher rates of confusion and delirium than alternative opioids.[8][19]
Normeperidine accumulation produces a distinct form of psychological toxicity: agitation, anxiety, irritability, and disorientation that can progress to delirium with paranoid features.[4] This state is mechanistically distinct from opioid sedation and may be mistaken for undertreated pain — prompting dose increases that worsen the underlying toxicity.
Tolerance & Dependence
Tolerance to pethidine's analgesic and euphoric effects develops through standard μ-opioid receptor mechanisms.[15] Physical dependence develops rapidly with regular use. Withdrawal follows the general opioid pattern — watery eyes, runny nose, diarrhea, muscle aches, insomnia, low mood — with an additional concern: declining normeperidine levels during withdrawal may produce tremors, anxiety, and potentially seizures in heavy users.
Cross-tolerance to other μ-opioid agonists is present but incomplete. When switching from pethidine to another opioid, reduced doses are used to account for this.[20] Dependence liability is high — reflected in Schedule II (US) and Class A (UK) classification.
Drug Interactions
Pethidine's multi-target pharmacology produces a wider range of dangerous interactions than most opioids.
The MAOI–pethidine interaction is an absolute contraindication — the most dangerous drug interaction in opioid pharmacology. It can produce either serotonin syndrome (hyperthermia, rigidity, involuntary contractions, death) or severe depression (coma, respiratory failure, cardiovascular collapse).[18][13] Risk persists for 14 days after MAOI discontinuation. SSRIs combined with pethidine also produce serotonin syndrome.[12]
Alcohol, benzodiazepines, other opioids, barbiturates, GHB, and GBL produce additive respiratory depression when combined with pethidine.[3] Drugs that inhibit liver enzyme CYP3A4 (including ketoconazole, ritonavir, and grapefruit juice) can elevate pethidine blood levels to dangerous concentrations.[3] Mixed opioid agonist-antagonists (buprenorphine, nalbuphine) can trigger withdrawal in pethidine-dependent individuals.[3]
Contraindications
Absolute:
- MAOI use within the preceding 14 days[18][13]
- Severe kidney impairment — normeperidine accumulation produces seizures not reversible by naloxone[6]
- Use exceeding 48 hours — normeperidine accumulates regardless of kidney function[3]
Relative:
- Older adults — 2023 AGS Beers Criteria: always avoid[8]
- Liver impairment — bioavailability increases to 80–90% and half-life doubles[14]
- Seizure disorders — normeperidine lowers seizure threshold
- Sickle cell disease — documented normeperidine toxicity[7][21]
- Concurrent SSRI use — serotonin syndrome risk[12]
- Concurrent CYP3A4 inhibitors — elevated blood levels[3]
Harm Reduction[edit]
Forms & Identification
Pethidine encountered outside clinical settings is almost always diverted pharmaceutical product — tablets, ampoules, or syrup bearing manufacturer labelling. Unlike heroin or illicitly manufactured fentanyl, clandestine production of pethidine is rare. The primary identification concern is verifying that a diverted product is genuine and unexpired.
For loose tablets or powder of uncertain origin, fentanyl test strips can help rule out substitution with illicitly manufactured fentanyl analogues, which are active at far lower doses and carry substantially higher overdose risk.
Guidelines
- Test any substance of uncertain provenance — particularly for fentanyl contamination
- Start with the lowest available dose and wait for full onset before redosing
- Do not use for more than 48 hours consecutively — normeperidine accumulates regardless of kidney function
- Have naloxone available and ensure a companion knows how to use it
- Eat lightly before oral dosing to reduce nausea
- Stay hydrated — anticholinergic effects cause dry mouth
- Avoid driving or operating machinery
Set & Setting
Opioid use is safest in the presence of at least one sober observer who knows what has been taken and can respond to an emergency. A calm, comfortable environment reduces the risk of anxiety-driven redosing. Avoid using alone — respiratory depression can progress from drowsiness to death without the user's awareness.
Aftercare & integration. After pethidine use, allow the full duration of effects to pass before driving or making important decisions. Nausea and constipation may persist beyond the analgesic window. Stay hydrated and eat small, bland meals.
If use occurred in a medical context and dependence is a concern, discuss this openly with the prescribing clinician. If use was non-medical, reflect honestly on the motivation — opioid euphoria can establish psychological patterns that precede physical dependence.
Recovery & Support
Pethidine dependence responds to the same evidence-based treatments used for other opioid use disorders. Medication-assisted treatment with buprenorphine or methadone is the standard of care and substantially reduces relapse and overdose death. Naltrexone is an alternative for individuals who have completed detoxification.
Peer support through organisations such as SMART Recovery or Narcotics Anonymous provides community and structure during recovery. If physical dependence has developed, medically supervised tapering is safer than abrupt cessation — opioid withdrawal is intensely uncomfortable and its distress drives relapse.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognising an emergency: Slow, shallow, or stopped breathing; blue or grey lips and fingertips; unresponsiveness to voice or pain; gurgling or snoring sounds during unconsciousness. Seizures (jerking, rigidity) may indicate normeperidine toxicity rather than standard opioid overdose.
Immediate steps:
- 1. Call emergency services immediately
- 2. Administer naloxone if available — naloxone reverses opioid respiratory depression but does not stop normeperidine seizures
- 3. If the person is unconscious but breathing, place in the recovery position
- 4. If breathing has stopped and naloxone is unavailable, begin rescue breathing
- 5. For seizures: do not restrain; clear the area of hard objects; do not place anything in the mouth
- 6. Do not induce vomiting
What to tell the dispatcher: The substance taken (pethidine, meperidine, or Demerol), the amount if known, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect callers who report an overdose from drug-related prosecution.
Reversal agent: Naloxone reverses pethidine's opioid effects (respiratory depression, sedation) but does not reverse normeperidine-induced seizures. Benzodiazepines are required for seizure control.
Legal Status[edit]
Pethidine is internationally controlled under the United Nations Single Convention on Narcotic Drugs (1961), listed as a Schedule I substance — indicating high abuse potential with recognised medical uses.[2] All signatory nations are required to implement domestic controls. Pethidine carries the highest level of restriction in major jurisdictions, reflecting both its abuse potential and the availability of safer therapeutic alternatives.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International | Schedule I (UN Single Convention on Narcotic Drugs, 1961) | High abuse potential; accepted medical use; requires import/export authorisation[2] |
| United States | Schedule II (Controlled Substances Act) | High abuse potential; accepted medical use with severe restrictions; DEA registration required for prescribing[3] |
| United Kingdom | Class A (MDA 1971); Schedule 2 (MDR 2001) | Maximum penalties for unlawful supply: life imprisonment; Schedule 2 permits medical prescription under strict controls[22] |
| Australia | Schedule 8 (Controlled Drug)citation needed | Requires authority prescription in most states; restricted prescribing |
| Canada | Schedule I (CDSA)citation needed | Controlled substance requiring prescriber authorisation |
Australia and Canada classifications require editorial verification from primary sources.
references
- [1]
- [2]
- [3]
- [4] ^abcdHershey LA (1983) Meperidine and central neurotoxicity. — Annals of Internal Medicine PMID:6838077
- [5]
- [6] ^abcReutens DC, Stewart-Wynne EG (1989) Norpethidine induced myoclonus in a patient with renal failure. — Journal of Neurology, Neurosurgery & Psychiatry doi:10.1136/jnnp.52.12.1450